论文部分内容阅读
目的探讨吸烟对支气管哮喘患者吸入糖皮质激素(ICS)疗效的影响。方法对不吸烟(15例)及吸烟(15例)的支气管哮喘患者每日吸入布地奈德治疗,必要时可吸入β2受体激动剂。治疗4周,治疗前后进行肺功能测定。结果不吸烟组患者治疗后的清晨PEF、睡前PEF、FEV1%均较治疗前改善(P<0.05)。而吸烟组患者在治疗前后上述指标却变化不大(P>0.05)。结论吸烟降低了哮喘患者对ICS的治疗反应性,对吸烟的哮喘患者,治疗可能需要特殊的调整。
Objective To investigate the effect of smoking on the efficacy of inhaled glucocorticoid (ICS) in patients with bronchial asthma. Methods Non-smoking (15 cases) and smoking (15 cases) patients with bronchial asthma daily inhalation of budesonide, if necessary, inhaled β2 agonists. After 4 weeks of treatment, pulmonary function tests were performed before and after treatment. Results The PEF, PEF and FEV1% of non-smoker group after treatment were significantly improved compared with before treatment (P <0.05). The smoking group patients before and after treatment in the above indicators did not change much (P> 0.05). Conclusion Smoking reduces the therapeutic response to ICS in asthmatic patients, and treatment may be subject to special adjustments in smokers with asthma.